Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review

about

Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review

Item

http://www.wikidata.org/entity/Q42701796

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Switching biological disease-m ...... a systematic literature review

@en

Switching biological disease-m ...... a systematic literature review

@nl

type

Item

label

Switching biological disease-m ...... a systematic literature review

@en

Switching biological disease-m ...... a systematic literature review

@nl

prefLabel

Switching biological disease-m ...... a systematic literature review

@en

Switching biological disease-m ...... a systematic literature review

@nl

P1476

Switching biological disease-m ...... a systematic literature review

@en

P2093

Alejandro Balsa

http://www.w3.org/2001/XMLSchema#string

Chamaida Plasencia-Rodríguez

http://www.w3.org/2001/XMLSchema#string

Eugenio de Miguel

http://www.w3.org/2001/XMLSchema#string

Jordi Gratacós

http://www.w3.org/2001/XMLSchema#string

Petra Diaz Del Campo

http://www.w3.org/2001/XMLSchema#string

Victoria Navarro-Compán

http://www.w3.org/2001/XMLSchema#string

P2860

Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis.

Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.

Preliminary definitions of 'flare' in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative.

P304

e000524

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/RMDOPEN-2017-000524

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29071119

http://www.w3.org/2001/XMLSchema#string

P932

5640114

http://www.w3.org/2001/XMLSchema#string